Investment banking firm Àrgentil Capital Partners has made an undisclosed amount of equity investment in Nigerian healthcare company Sygen Pharmaceuticals Limited through investment vehicle Consumer Growth Partners along with other undisclosed investors.
Incorporated in 2019, Sygen Pharmaceuticals Limited has produced and distributed pharmaceutical products for more than half a century in Nigeria. Prior to this, Sygen acquired operating assets of Nigerian German Chemicals in 2019. Àrgentil invests in small and medium size enterprises through Àrgentil Principal Investment Portfolio II whose key focus areas include Nigeria.
Access To 12-Month WT Membership
Access To WT's Conferences & Events
Access To All WT's Research Reports On Africa
Access To Podcasts, Video Content & Recordings
Access To All Premium Newsletters
Unlimited Access To WT's Content Archive